Moderna Narrows Q4 Loss, Maintains 10% Growth Target as FDA Delays RSV Approval
Moderna narrowed its fourth-quarter loss and beat revenue and EPS estimates while reiterating a 10% growth target for 2026. Shares dipped after the FDA delayed approval of its RSV vaccine candidate, pushing back the anticipated launch timeline.
1. Fourth-Quarter Performance and Guidance
Moderna reported a narrowed fourth-quarter loss while exceeding consensus on both earnings and revenue. Management reiterated its target of 10% revenue growth for 2026, driven by ongoing COVID-19 vaccine sales and advancing pipeline programs.
2. FDA Setback and Market Reaction
Shares slipped after the FDA postponed its decision on Moderna’s respiratory syncytial virus vaccine candidate, delaying the expected commercial launch. The regulatory delay introduces uncertainty around near-term revenue contributions from the RSV program.
Related News
NVDA
NVIDIA Forecasts Zero China Data Center Revenue, Targets $20B Vera CPU Sales
NVDA•
INTU
Intuit to Launch AI-Driven Platforms in August, Cuts 17% Workforce to Fund Growth
INTU•
NVDA
Nvidia posts US$81.6B Q1 revenue, forecasts US$91B for Q2
NVDA•
NVDA
Hedge Funds Back Nvidia-Powered AI Data Centers as Shares Fall 1.3% After $80B Buyback
NVDA•
YSG
Yatsen Raises US$60M in First Tranche of US$120M Convertible Note Placement
YSG•
Sources
WF